Biopharma

Where globally is innovation occurring and what factors – industry, regulatory, and academia – are helping developers get their products to market? Here, DDW Editor Reece Armstrong explores the global hubs of innovation for cell and gene therapies. Since the approval of Kymirah in 2017, the cell and gene therapy sector has emerged as an […]

Current methods to generate cells from human-induced pluripotent stem cells (iPSCs) lack reproducibility and scalability. This raises challenges for disease research, drug discovery and cell therapy development due to unreliable data and long experimental timelines. However, there is a new technology on the block, enabling reproducible, consistent and scalable production of physiologically relevant human cell […]

Biopharmaceutical company TikoMed has announced two new appointments to its Board of Directors as the company focuses on its ILB drug programme. TikoMed has appointed Tara Heitner and Pete Zorn to its Board of Directors. Tara Heitner has more than 15 years of experience in the biopharmaceutical industry and has been involved in the development […]

Some 5% of commercially available research compounds are sold as salt forms. These can have better properties than their parents, including preferable stability, solubility, bioavailability, and manufacturability. By selecting the correct salt form for an assay or as a reagent, scientists can optimise their research projects, says Andrievs Auseklis Auzin, Developer, Molport, Latvia. The research […]

By Mark White, Associate Director of Biopharma Product Marketing at Bio-Rad and Marwan Alsarraj, Biopharma Segment Manager, Digital Biology Group. Until about 25 years ago, the best treatment option for someone with blood cancer was either toxic radiation and chemotherapy or a bone marrow transplant that posed additional life-threatening risks to the patient1. But decades […]

This e-book, sponsored by Evonetix, contains exclusive insight from industry experts on how synthetic biology is innovating and advancing drug discovery.   Key topics include:   Four key approaches to synthetic biology  The global advances in synthetic biology drug discovery Why synthetic biology is the next big step for biopharma  What an organoid innovation centre means for 3D biology […]

This e-book, sponsored by Evonetix, contains exclusive insight from industry experts on how synthetic biology is innovating and advancing drug discovery.   Key topics include:   Four key approaches to synthetic biology  The global advances in synthetic biology drug discovery Why synthetic biology is the next big step for biopharma  What an organoid innovation centre means for 3D biology […]

Ian Hollingsworth, Associate Director of product development at Boyds, the global drug development consultancy, explains the benefits to the drug development lifecycle of building strong partnerships with external consultants, and when and how to get the best from them. Everyone can benefit from sharing experiences and learning from experts and specialists outside of their workplace […]

ELRIG’s free flagship annual Drug Discovery meeting — renowned for its networking opportunities and high calibre of scientific programme — is now in its 16th year.   This year’s meeting will be held in-person, from 4–5th October at the ExCel in London — a city at the heart of European life sciences innovation.   For Drug Discovery […]

This e-book by NanoTemper looks at the workflows researchers are using in the biologics space and the benefits dynamic light scattering (DLS) offers. You will find out: What biologics are and why they’re important How DLS gives you information about your samples and what that data means Tips and considerations when designing your own DLS […]